Metalloproteinases and Recurrent Corneal Erosion Syndrome (MERCURE)

Fondation Ophtalmologique Adolphe de Rothschild

Status: Completed

Conditions: Recurrent Corneal Erosion Syndrome

Treatments: Other: in vitro immuno-histo-chemical analysis of corneal epithelium

Study type: Observational

Funder types: NETWORK

Identifiers

NCT02891694

EGN_2016_8

Details and patient eligibility

About

Recurrent corneal erosion (RCE) syndrome can be observed either in the context of a dystrophy of the basement membrane or following corneal trauma. This syndrome is characterized by recurrent episodes of ocular pain more or less associated with localized separations between the outer epithelium and the epithelial basal lamina (basement membrane) because of anchorage abnormalities between these two corneal layers. This could be the result of an increased expression of metalloproteinases cleaving the hemidesmosomes which anchor epithelium to the basement membrane.

The investigators hypothesis is that episodes of RCEs are favored by a hyper- expression of matricial metalloprotease 9 (MMP-9) induced by EMMPRIN and Galectin-3. The identification of such induction could lead to development of therapeutics inhibiting EMMPRIN and Galectin- 3 in the RCE syndrome.

Enrollment: 19 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18 years old
• Recurrent Corneal Erosion Syndrome, with - failure of medical treatment and therapeutic photokeratectomy scheduled
• Photorefractive surgical keratectomy (control patients)

Exclusion criteria

• Opposition to participation in the study
• Known pregnancy or breast-feeding patient
• No medical insurance coverage

Trial design

19 participants in 2 patient groups

recurrent corneal erosion

Treatment:

Other: in vitro immuno-histo-chemical analysis of corneal epithelium

control patients (refractive surgery)

Treatment:

Other: in vitro immuno-histo-chemical analysis of corneal epithelium